Tyrosine Kinase JAK Inhibitors market was valued at US$ 30480 million in 2022 and is anticipated to reach US$ 550830 million by 2029, witnessing a CAGR of 50.6% - Valuates Reports

Tyrosine Kinase JAK Inhibitors market was valued at US$ 30480 million in 2022 and is anticipated to reach US$ 550830 million by 2029, witnessing a CAGR of 50.6% during the forecast period 2023-2029.

Get sample report - https://reports.valuates.com/request/sample/QYRE-Auto-36C576/Global_Tyrosine_Kinase_JAK_Inhibitors_Market_Research_Report_2020

Janus kinase inhibitors, also known as JAK inhibitors or jakinibs, are a type of medication that functions by inhibiting the activity of one or more of the Janus kinase family of enzymes (JAK1, JAK2, JAK3, TYK2), thereby interfering with the JAK-STAT signaling pathway.
These inhibitors have therapeutic application in the treatment of cancer and inflammatory diseases such as rheumatoid arthritis. There is interest in their use for various skin conditions. JAK3 inhibitors are attractive as a possible treatment of various autoimmune diseases since its functions is mainly restricted to lymphocytes. Development for a selective JAK3 inhibitors are ongoing.
In the report, we only count drugs for human beings. And the 1 unit is 1 tablet.
The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The classification of Tyrosine Kinase JAK Inhibitors includes Tofacitinib, Ruxolitinib and Baricitinib, and the proportion of Ruxolitinib is about 56%.
Tyrosine Kinase JAK Inhibitors is widely used in Rheumatoid Arthritis (RA), Polycythemia Vera (PCV) and Myelofibrosis (MF). The most proportion of Tyrosine Kinase JAK Inhibitors is for Rheumatoid Arthritis (RA), and the proportion is about 37%.
North America is the largest consumption place, with a consumption market share nearly 56%. Following North America, Europe is the second largest consumption place with the consumption market share of 39%.
Market competition is intense. Pfizer, Incyte, Novartis, Eli Lilly are the leaders of the industry. Pfizer is the leader of this industry with about 42% market sharers.

Segment by Type
Tofacitinib
Ruxolitinib
Baricitinib

Segment by Application
Rheumatoid Arthritis (RA)
Polycythemia Vera (PCV)
Myelofibrosis (MF)
Others

Get detailed report - https://reports.valuates.com/market-reports/QYRE-Auto-36C576/global-tyrosine-kinase-jak-inhibitors

Similar report -

https://reports.valuates.com/market-reports/QYRE-Auto-4Q1256/global-janus-kinase-jak-inhibitors

https://reports.valuates.com/market-reports/QYRE-Auto-33G5892/global-jak-inhibitor-drug

Valuates offers an extensive collection of market research reports that helps companies to take intelligent strategical decisions based on current and forecasted Market trends.

Phone:
U.S. (TOLL FREE) : +1 (315) 215-3225
India: +91 8040957137

Email Id:
Please reach us at sales@valuates.com

This release was published on openPR.